BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23718573)

  • 21. Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis- A randomized pilot study.
    Kedarisetty CK; Bhardwaj A; Kumar G; Rastogi A; Bihari C; Kumar M; Sarin SK
    Indian J Gastroenterol; 2021 Feb; 40(1):41-49. PubMed ID: 33772456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
    Ji HF; Sun Y; Shen L
    Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3-year prospective cohort study.
    Chang ML; Tai J; Cheng JS; Chen WT; Yang SS; Chiu CH; Chien RN
    Diabetes Obes Metab; 2024 Jul; 26(7):2969-2978. PubMed ID: 38685616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.
    Corey KE; Vuppalanchi R; Wilson LA; Cummings OW; Chalasani N;
    Aliment Pharmacol Ther; 2015 Feb; 41(3):301-9. PubMed ID: 25429853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
    Zhang W; Wu R; Zhang F; Xu Y; Liu B; Yang Y; Zhou H; Wang L; Wan K; Xiao X; Zhang X
    Clin Exp Pharmacol Physiol; 2012 Dec; 39(12):1026-33. PubMed ID: 23127227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
    Bril F; Biernacki DM; Kalavalapalli S; Lomonaco R; Subbarayan SK; Lai J; Tio F; Suman A; Orsak BK; Hecht J; Cusi K
    Diabetes Care; 2019 Aug; 42(8):1481-1488. PubMed ID: 31332029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis.
    Sumida Y; Naito Y; Tanaka S; Sakai K; Inada Y; Taketani H; Kanemasa K; Yasui K; Itoh Y; Okanoue T; Yoshikawa T
    Hepatogastroenterology; 2013 Sep; 60(126):1445-50. PubMed ID: 23933938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of vitamin E on chronic hepatitis C genotype 3: a randomized, double-blind, placebo-controlled study.
    Bunchorntavakul C; Wootthananont T; Atsawarungruangkit A
    J Med Assoc Thai; 2014 Nov; 97 Suppl 11():S31-40. PubMed ID: 25509693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].
    Heebøll S; Kazankov K; Poulsen MK; Vilstrup H; Grønbæk H
    Ugeskr Laeger; 2012 Feb; 174(8):488-90. PubMed ID: 22348670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H; Dufour JF
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
    Lomonaco R; Sunny NE; Bril F; Cusi K
    Drugs; 2013 Jan; 73(1):1-14. PubMed ID: 23329465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
    Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study.
    Geier A; Eichinger M; Stirnimann G; Semela D; Tay F; Seifert B; Tschopp O; Bantel H; Jahn D; Marques Maggio E; Saleh L; Bischoff-Ferrari HA; Müllhaupt B; Dufour JF
    Scand J Gastroenterol; 2018 Sep; 53(9):1114-1120. PubMed ID: 30270688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial.
    Khoshbaten M; Beheshtirouy S; Shayanrad S; Gharekhani A; Rezaee H
    Drug Res (Stuttg); 2023 Apr; 73(4):232-237. PubMed ID: 36791804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
    Angelico F; Burattin M; Alessandri C; Del Ben M; Lirussi F
    Cochrane Database Syst Rev; 2007 Jan; (1):CD005166. PubMed ID: 17253544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonalcoholic fatty liver disease: new treatments.
    Hardy T; Anstee QM; Day CP
    Curr Opin Gastroenterol; 2015 May; 31(3):175-83. PubMed ID: 25774446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.